<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297166</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ-006</org_study_id>
    <secondary_id>2010-022663-35</secondary_id>
    <nct_id>NCT01297166</nct_id>
  </id_info>
  <brief_title>A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris</brief_title>
  <official_title>A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the anti-psoriatic effect of LEO 27989 ointment and&#xD;
      calcipotriol plus LEO 27989 ointment, using the psoriasis plaque test modified from the&#xD;
      method developed by KJ Dumas and JR Scholtz.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in Total Clinical Score (TCS) of clinical symptoms (sum of erythema, scaling and infiltration) at end of treatment compared to baseline.</measure>
    <time_frame>3 weeks</time_frame>
    <description>TCS range from 0 (all symptoms absent) to 9 (all symptoms severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical sympton scores</measure>
    <time_frame>3 weeks</time_frame>
    <description>Absolute change in single clinical symptom score: erythema, scaling, infiltration at end of treatment and individual visits compared to baseline.&#xD;
Change in Total Clinical Score (TCS) at individual visits compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion thickness</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change in lesion thickness measured by ultrasound at each assessment compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical and histologic scoring of biopsy material</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-subject variability</measure>
    <time_frame>3 weeks</time_frame>
    <description>The intra-subject variability of changes from baseline to end of treatment of TCS and skin thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 27989 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 27989 ointment</intervention_name>
    <description>once daily application, 3weeks</description>
    <arm_group_label>LEO 27989 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus LEO 27989 ointment</intervention_name>
    <description>once daily application, 3weeks</description>
    <arm_group_label>LEO 27989 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol ointment</intervention_name>
    <description>once daily application, 3weeks</description>
    <arm_group_label>LEO 27989 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle ointment</intervention_name>
    <description>once daily application, 3weeks</description>
    <arm_group_label>LEO 27989 ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects having understood and signed an informed consent form&#xD;
&#xD;
          -  Age 18 years or above&#xD;
&#xD;
          -  Males, or females of non-child bearing potential&#xD;
&#xD;
          -  All skin types&#xD;
&#xD;
          -  Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms and/or&#xD;
             legs and/or trunk.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Male who are not willing to use a local contraception (such as condom) for the entire&#xD;
             duration of the study, and refrain from fathering a child within 3 months following&#xD;
             the last study drug application&#xD;
&#xD;
          -  Females who are pregnant, of child-bearing potential and who wish to become pregnant&#xD;
             during the study, or who are breast feeding&#xD;
&#xD;
          -  Systemic treatment with biological therapies (marketed or not marketed) with a&#xD;
             possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months&#xD;
             (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks /5 half-lives&#xD;
             (which-ever is longer) for experimental biological products prior to randomisation and&#xD;
             during the study&#xD;
&#xD;
          -  Systemic treatments with all other therapies than biologicals, with a potential effect&#xD;
             on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within&#xD;
             the 4-week period prior to randomisation and during the study&#xD;
&#xD;
          -  Subjects using one of the following topical drugs for the treatment of psoriasis&#xD;
             within the 4 week period prior to randomisation and during the study:&#xD;
&#xD;
               -  Potent or very potent (WHO group III-IV) corticosteroids&#xD;
&#xD;
               -  PUVA or Grenz ray therapy&#xD;
&#xD;
          -  Subjects using one of the following topical drugs for the treatment of psoriasis&#xD;
             within two weeks prior to randomisation and during the study:&#xD;
&#xD;
               -  WHO group I-II corticosteroids (except if used for treatment of scalp and/or&#xD;
                  facial psoriasis)&#xD;
&#xD;
               -  Topical retinoids&#xD;
&#xD;
               -  Vitamin D analogues&#xD;
&#xD;
               -  Topical immunomodulators (e.g. macrolides)&#xD;
&#xD;
               -  Anthracen derivatives&#xD;
&#xD;
               -  Tar&#xD;
&#xD;
               -  Salicylic acid&#xD;
&#xD;
               -  UVB therapy&#xD;
&#xD;
          -  Subjects using emollients on the target plaques within one week before randomisation&#xD;
             and during the study&#xD;
&#xD;
          -  Initiation of, or expected changes to concomitant medication that may affect psoriasis&#xD;
             vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) within&#xD;
             2 weeks prior to the randomisation and during the study&#xD;
&#xD;
          -  Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular&#xD;
             psoriasis&#xD;
&#xD;
          -  Subjects with known/suspected disorders of calcium metabolism associated with&#xD;
             hypercalcaemia based on medical history&#xD;
&#xD;
          -  Subjects with a positive Hepatitis B, Hepatitis C or HIV test&#xD;
&#xD;
          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an&#xD;
             agent which has not yet been made available for clinical use following registration)&#xD;
             within the 4 week period prior to randomisation or longer, if the class of the&#xD;
             substance requires a longer washout as defined above (e.g., biological treatments)&#xD;
&#xD;
          -  Subjects with current participation in any other interventional clinical, based on&#xD;
             interview of the subject&#xD;
&#xD;
          -  Subjects with known or suspected hypersensitivity to component(s) of the&#xD;
             investigational products&#xD;
&#xD;
          -  History of any severe disease or serious current condition (based on subject interview&#xD;
             and/or results of screening physical examination) which, in the opinion of the&#xD;
             Investigator, would put the subject at risk by participating in the study or would&#xD;
             interfere significantly with the evaluation of study results or the study course (e.g.&#xD;
             cancer, severe cardiopathy, severe renal insufficiency, severe hepatic insufficiency).&#xD;
&#xD;
          -  Subjects with a positive Hepatitis B, Hepatitis C or HIV test&#xD;
&#xD;
          -  Subjects with any concomitant medical or dermatological disorder(s) which might&#xD;
             preclude accurate evaluation of the psoriasis on the test areas&#xD;
&#xD;
          -  Subjects foreseeing an intensive solar exposure during the study (UV radiation, etc.)&#xD;
             or having been exposed within two weeks preceding the screening visit&#xD;
&#xD;
          -  Subjects with any contraindication to skin biopsy procedures: e.g., allergy to local&#xD;
             anaesthetics, topical antiseptics (chlorhexidine), bleeding tendency, treatment with&#xD;
             anticoagulant drugs, history of poor wound healing, and history of vasovagal&#xD;
             hypotension or syncope.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Queille-Roussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Pharmacologie Clinique Applique a la Dermatologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPCAD</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

